LYEL
Lyell Immunopharma, Inc.
NASDAQ · USHealthcareBiotechnology
$12.92-3.00%
Price as of Jul 20, 2026
LYEL profitability
Lyell Immunopharma, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -7422.6%
- EBITDA margin
- —
- EBIT margin
- —
- Net margin
- —
- Free cash flow margin
- —
Returns
- Return on equity
- -90.0%
- Return on assets
- -70.3%
- Return on invested capital
- -59.5%
- Asset turnover
- 0.00x
Cash efficiency
- Cash from operations
- -$133.8M
- Cash per share
- $11
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.